Glenmark Receives FDA Approval for Generic Progesterone Vaginal Inserts in $59.2 Million Market
核心洞察
Glenmark Pharmaceuticals received final FDA approval for Progesterone Vaginal Inserts, 100 mg, determined to be bioequivalent and therapeutically equivalent to Ferring's Endometrin.
The generic product enters a market worth approximately $59.2 million in annual sales according to IQVIA data for the 12-month period ending February 2026.
The approval strengthens Glenmark's women's healthcare portfolio and supports the company's mission to expand access to quality and affordable medicines in the U.S. market.
Glenmark Pharmaceuticals Limited has secured final approval from the U.S. Food and Drug Administration for Progesterone Vaginal Inserts, 100 mg, marking the company's entry into a women's healthcare market valued at approximately $59.2 million annually. The FDA determined Glenmark's formulation to be bioequivalent and therapeutically equivalent to the reference listed drug Endometrin Vaginal Inserts, 100 mg manufactured by Ferring Pharmaceuticals (搜索) Inc.
Market Opportunity and Distribution
According to IQVIA sales data for the 12-month period ending February 2026, the Endometrin Vaginal Inserts, 100 mg market achieved annual sales of approximately $59.2 million. This market includes both the brand product and all available therapeutic equivalents. Glenmark Pharmaceuticals Inc., USA will handle distribution of the generic product in the United States.
The approval represents a significant addition to Glenmark's U.S. portfolio, particularly in the women's healthcare segment where the company has been focusing its expansion efforts.
Strategic Focus on Women's Healthcare
Marc Kikuchi, President & Business Head, North America, emphasized the strategic importance of this approval for the company's women's healthcare initiatives. "At Glenmark, we remain focused on expanding access to quality and affordable medicines while continuing to strengthen our portfolio in the U.S.," Kikuchi stated. "This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women's healthcare."
Regulatory Details
The FDA approval covers Glenmark's Progesterone Vaginal Inserts, 100 mg under the Abbreviated New Drug Application process, with the product receiving NDA 022057 designation. The approval confirms bioequivalence to Ferring's Endometrin, though Glenmark's product is only approved for the specific indications listed in its approved label and will not be marketed for all reference drug indications.
Company Profile
Glenmark Pharmaceuticals operates as a global, research-led pharmaceutical company with 11 manufacturing facilities across four continents and six R&D centers. The company maintains a commercial presence in over 80 countries, delivering a diversified portfolio spanning branded, innovative, generics, and consumer health products. The company focuses particularly on respiratory, dermatology, and oncology therapeutic areas. Scrip 100 recognized Glenmark among the top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.